ArticleAnnals of surgical oncology2026
Recurrence Patterns of Resected Ampullary Adenocarcinoma and Implications for Multimodal Therapy: A Hidden Genome-Derived Analysis from the Ampullary Cancer Collaborative.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
Abstract
backgroundAmpullary adenocarcinoma is characterized by significant clinical heterogeneity that may preclude rational application of adjuvant therapies. The Hidden Genome Classifier defines distinct prognostic subtypes of ampullary adenocarcinoma. The impact of genomic subtype on recurrence patterns is unknown and may provide novel biomarkers to optimize treatment selection.
methodsThe previously validated Hidden Genome Classifier was applied to an international, six-institution cohort of 218 patients with resected ampullary adenocarcinoma. Genomic classification was correlated with pattern of disease recurrence (local vs distant) and with recurrence-free survival (RFS) and overall survival (OS) using the log-rank test and Cox proportional hazard models.
resultsGenomic subtype, but not immunohistologic subtype, was associated with RFS (colorectal [55.5 months] vs pancreas/distal bile duct [18.3 months]; p = 0.022). Isolated local recurrence was infrequent (22.4%) and did not vary across genomic subtypes (p = 0.933), traditional immunohistologic subtypes (p = 0.505), or margin status (p = 0.557). The pancreas/distal bile duct genomic subtype was associated with a greater rate of distant recurrence (44.0% vs 21.0%; p = 0.005). In a multivariable model accounting for American Joint Committee on Cancer (AJCC) stage, the use of radiation was not associated with RFS (ref: surgery alone; radiation: hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.49-1.39). Adjuvant chemotherapy was associated with improved OS (ref: surgery alone; HR, 0.52; 95% CI, 0.32-0.84; p = 0.008).
conclusionsGenomic and clinical biomarkers failed to identify patients at increased risk for local recurrence for whom radiation may be best applied. Distant recurrence was common, and adjuvant chemotherapy was associated with improved survival.
Indexed as
Identifiers
42758445What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.